<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694443/" ref="ordinalpos=7&amp;ncbi_uid=1934988&amp;link_uid=PMC2694443" image-link="/pmc/articles/PMC2694443/figure/F8/" class="imagepopup">Fig. 8. A model of the relationship between BMPR1A and canonical Wnt <span class="highlight" style="background-color:">signaling</span> in mouse bone.  From: BMP <span class="highlight" style="background-color:">signaling</span> negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt <span class="highlight" style="background-color:">pathway</span>. </a></div><br /><div class="p4l_captionBody">BMPR1A signaling upregulates sclerostin expression, leading to an inhibition of canonical Wnt signaling and a decrease in bone mass by upregulating osteoclastogenesis through the RANKL-OPG pathway. Sclerostin, the SOST gene product, acts as a downstream effector of BMPR1A signaling, an inhibitor of canonical Wnt signaling and a bone mass-determining factor. Broken line indicates another possibility: that BMP signaling directly upregulates osteoclastogenesis through the RANKL-OPG pathway.</div></div>